Evidence map›Paper›PMID 36903811›Full record

ArticleNanomaterials (Basel, Switzerland)2023

Magnetic Nanoclusters Stabilized with Poly[3,4-Dihydroxybenzhydrazide] as Efficient Therapeutic Agents for Cancer Cells Destruction.

Ioana Baldea, Anca Petran, Adrian Florea, Alexandra Sevastre-Berghian, Iuliana Nenu, Gabriela Adriana Filip, Mihai Cenariu, Maria Teodora Radu, Cristian Iacovita

Full text read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. In Vitro Antitumor Effects of Melittin Attached to FeMolecules (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Gels (Basel, Switzerland) · 2025
    Article
  6. Evaluation of Antiproliferative Properties of CoMnZn-FePharmaceuticals (Basel, Switzerland) · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ioana BaldeaDepartment of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, Clinicilor 1-3 Str., 400012 Cluj-Napoca, Romania.ORCID 0000-0003-4046-7310
Anca PetranNational Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donat Str., 400293 Cluj-Napoca, Romania.
Adrian FloreaDepartment of Cell and Molecular Biology, Faculty of Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Pasteur 6 Str., 400349 Cluj-Napoca, Romania.ORCID 0000-0002-0898-7626
Alexandra Sevastre-BerghianDepartment of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, Clinicilor 1-3 Str., 400012 Cluj-Napoca, Romania.
Iuliana NenuDepartment of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, Clinicilor 1-3 Str., 400012 Cluj-Napoca, Romania.
Gabriela Adriana FilipDepartment of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, Clinicilor 1-3 Str., 400012 Cluj-Napoca, Romania.ORCID 0000-0002-7447-4925
Mihai CenariuDepartment of Biochemistry, University of Agricultural Sciences and Veterinary Medicine, Calea Manastur 3-5 Str., 400658 Cluj-Napoca, Romania.
Maria Teodora RaduNational Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donat Str., 400293 Cluj-Napoca, Romania.
Cristian IacovitaDepartment of Pharmaceutical Physics-Biophysics, Faculty of Pharmacy, "Iuliu Hatieganu" University of Medicine and Pharmacy, 6 Pasteur Str., 400349 Cluj-Napoca, Romania.ORCID 0000-0001-5398-1445

Funding

Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii PN-III-P1-1.1-TE-2021-0498
6 · The paper itself

Abstract

Magnetic structures exhibiting large magnetic moments are sought after in theranostic approaches that combine magnetic hyperthermia treatment (MH) and diagnostic magnetic resonance imaging in oncology, since they offer an enhanced magnetic response to an external magnetic field. We report on the synthesized production of a core-shell magnetic structure using two types of magnetite nanoclusters (MNC) based on a magnetite core and polymer shell. This was achieved through an in situ solvothermal process, using, for the first time, 3,4-dihydroxybenzhydrazide (DHBH) and poly[3,4-dihydroxybenzhydrazide] (PDHBH) as stabilizers. Transmission electron microscopy (TEM) analysis showed the formation of spherical MNC, X-ray photoelectronic spectroscopy (XPS) and Fourier transformed infrared (FT-IR) analysis proved the existence of the polymer shell. Magnetization measurement showed saturation magnetization values of 50 emu/g for PDHBH@MNC and 60 emu/g for DHBH@MNC with very low coercive field and remanence, indicating that the MNC are in a superparamagnetic state at room temperature and are thus suitable for biomedical applications. MNCs were investigated in vitro, on human normal (dermal fibroblasts-BJ) and tumor (colon adenocarcinoma-CACO2, and melanoma-A375) cell lines, in view of toxicity, antitumor effectiveness and selectivity upon magnetic hyperthermia. MNCs exhibited good biocompatibility and were internalized by all cell lines (TEM), with minimal ultrastructural changes. By means of flowcytometry apoptosis detection, fluorimetry, spectrophotometry for mitochondrial membrane potential, oxidative stress, ELISA-caspases, and Western blot-p53 pathway, we show that MH efficiently induced apoptosis mostly via the membrane pathway and to a lower extent by the mitochondrial pathway, the latter mainly observed in melanoma. Contrarily, the apoptosis rate was above the toxicity limit in fibroblasts. Due to its coating, PDHBH@MNC showed selective antitumor efficacy and can be further used in theranostics since the PDHBH polymer provides multiple reaction sites for the attachment of therapeutic molecules.

Indexed as

apoptosismagnetic hyperthermiamagnetic nanoclustersmembrane pathwayoxidative stressp53 pathwaypoly[3,4-dihydroxybenzhydrazide]polydopamine analoguessolvothermal method

Identifiers

PMID36903811
PMCPMC10005337

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read65
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.